JP2010518167A - 併存する早漏及び勃起障害の治療 - Google Patents
併存する早漏及び勃起障害の治療 Download PDFInfo
- Publication number
- JP2010518167A JP2010518167A JP2009549684A JP2009549684A JP2010518167A JP 2010518167 A JP2010518167 A JP 2010518167A JP 2009549684 A JP2009549684 A JP 2009549684A JP 2009549684 A JP2009549684 A JP 2009549684A JP 2010518167 A JP2010518167 A JP 2010518167A
- Authority
- JP
- Japan
- Prior art keywords
- tramadol
- inhibitor
- pharmaceutically acceptable
- pde5
- acceptable form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
本発明は更に、トラマドール材料とホスホジエステラーゼ阻害剤からなるキットを提供する。キットは一つ以上の容器を含み、同容器の各々が、トラマドール材料とホスホジエステラーゼ阻害剤とを含有する。代替的に、キットは、トラマドール材料を保有する容器と、ホスホジエステラーゼ阻害剤を保有する異なる容器と、からなる。
懸濁剤は、活性成分に加えて、例えばエトキシ化イソステアリルアルコール、ポリオキシエチレンソルビタン及びソルビタンエステル、微結晶セルロース、メタ水酸化アルミニウム、ベントナイト、寒天及びトラガカント並びにそれらの混合物のような懸濁化剤を含み得る。
非経口投与に適した製薬組成物は、活性成分と組み合わせて、一つ以上の製薬的に許容される滅菌された等張の、水性溶液又は非水性溶液、分散剤、懸濁剤、乳剤、又は、使用直前に滅菌された注射可能な溶液又は分散剤に再構成される滅菌された散剤、若しくはその他の固形剤を含み、抗酸化剤、緩衝剤、同製剤を意図されたレシピエントの血液と等張とする溶質、又は懸濁化剤又は増粘剤を含み得る。
51歳の異性愛者の男性であって、長期間にわたり早漏及び勃起障害の病歴のある男性について泌尿器科医が診察し、同男性の早漏は「重度」(立証されたストップウォッチによる1分未満の膣内射精待ち時間及びスコア15の早漏診断ツール(PEDT))であり、かつ「軽度」から「中度」の勃起障害(スコア21の国際勃起障害指標(IIEF)の勃起機能(EF))を併存していると診断された。
Claims (19)
- ヒト男性における早漏と勃起障害との併存状態を治療する方法であって、性的行為の前の効果的な時間に、有効量のトラマドール材料と有効量のホスホジエステラーゼ(PDE)阻害剤とを前記男性に投与することを含む、方法。
- 前記トラマドール材料は、トラマドール又はその製薬的に許容される形態であり、PDE阻害剤は、PDE3、PDE4又はPDE5阻害剤である、請求項1に記載の方法。
- 前記PDE阻害剤は、PDE5阻害剤である、請求項2に記載の方法。
- 前記トラマドール材料は(±)シス−トラマドール又はその製薬的に許容される形態であり、前記PDE5阻害剤はシルデナフィル又はその製薬的に許容される形態、バルデナフィル又はその製薬的に許容される形態、タダラフィル又はその製薬的に許容される形態、或いは前記PDE5阻害剤の二つ以上の組み合わせである、請求項3に記載の方法。
- 前記トラマドール材料は(±)シス−トラマドール塩酸塩であり、かつ前記PDE5阻害剤はクエン酸シルデナフィル、バルデナフィル塩酸塩、タダラフィル、或いは前記PDE5阻害剤の二つ以上の組み合わせである、請求項4に記載の方法。
- 前記PDE5阻害剤はクエン酸シルデナフィルである、請求項5に記載の方法。
- 製薬的に許容される担体と、トラマドール材料と、ホスホジエステラーゼ(PDE)阻害剤と、からなる製薬組成物。
- 前記トラマドール材料は、トラマドール又はその製薬的に許容される形態であり、PDE阻害剤は、PDE3、PDE4又はPDE5阻害剤である、請求項7に記載の組成物。
- 前記PDE阻害剤は、PDE5阻害剤である、請求項8に記載の組成物。
- 前記トラマドール材料は(±)シス−トラマドール又はその製薬的に許容される形態であり、前記PDE5阻害剤はシルデナフィル又はその製薬的に許容される形態、バルデナフィル又はその製薬的に許容される形態、タダラフィル又はその製薬的に許容される形態、或いは前記PDE5阻害剤の二つ以上の組み合わせである、請求項9に記載の組成物。
- 前記トラマドール材料は(±)シス−トラマドール塩酸塩であり、かつ前記PDE5阻害剤はクエン酸シルデナフィル、バルデナフィル塩酸塩、タダラフィル、或いは前記PDE5阻害剤の二つ以上の組み合わせである、請求項10に記載の組成物。
- 前記PDE5阻害剤はクエン酸シルデナフィルである、請求項11に記載の組成物。
- (a)トラマドール材料と、ホスホジエステラーゼ(PDE)阻害剤と、を保持する容器、或いは
(b)トラマドール材料を保持する第一の容器と、ホスホジエステラーゼ(PDE)阻害剤を保持する第二の容器と、
からなる、キット。 - 前記トラマドール材料はトラマドール又はその製薬的に許容される形態であり、PDE阻害剤は、PDE3、PDE4又はPDE5阻害剤である、請求項13に記載のキット。
- 前記PDE阻害剤はPDE5阻害剤である、請求項14に記載のキット。
- 前記トラマドール材料は(±)シス−トラマドール又はその製薬的に許容される形態であり、かつ、前記PDE5阻害剤はシルデナフィル又はその製薬的に許容される形態、バルデナフィル又はその製薬的に許容される形態、タダラフィル又はその製薬的に許容される形態、或いは前記PDE5阻害剤の二つ以上の組み合わせである、請求項15に記載のキット。
- 前記トラマドール材料は(±)シス−トラマドール塩酸塩であり、かつ前記PDE5阻害剤はクエン酸シルデナフィル、バルデナフィル塩酸塩、タダラフィル、或いは前記PDE5阻害剤の二つ以上の組み合わせである、請求項16に記載のキット。
- 前記PDE5阻害剤はクエン酸シルデナフィルである、請求項17に記載のキット。
- 請求項13に記載のキットは、男性における早漏と勃起障害との併存状態を治療するためにトラマドール材料とPDE阻害剤とを使用するための指示書を更に含む、キット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88936907P | 2007-02-12 | 2007-02-12 | |
PCT/US2008/053710 WO2008100926A1 (en) | 2007-02-12 | 2008-02-12 | Treatment of comorbid premature ejaculation and erectile dysfunction |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013264162A Division JP2014077008A (ja) | 2007-02-12 | 2013-12-20 | 併存する早漏及び勃起障害を治療するための治療剤、製薬組成物及びキット |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010518167A true JP2010518167A (ja) | 2010-05-27 |
JP2010518167A5 JP2010518167A5 (ja) | 2012-01-26 |
Family
ID=39690490
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009549684A Pending JP2010518167A (ja) | 2007-02-12 | 2008-02-12 | 併存する早漏及び勃起障害の治療 |
JP2013264162A Pending JP2014077008A (ja) | 2007-02-12 | 2013-12-20 | 併存する早漏及び勃起障害を治療するための治療剤、製薬組成物及びキット |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013264162A Pending JP2014077008A (ja) | 2007-02-12 | 2013-12-20 | 併存する早漏及び勃起障害を治療するための治療剤、製薬組成物及びキット |
Country Status (17)
Country | Link |
---|---|
US (3) | US20080262094A1 (ja) |
EP (2) | EP2486927A1 (ja) |
JP (2) | JP2010518167A (ja) |
KR (3) | KR20150089085A (ja) |
CN (1) | CN101657101B (ja) |
AU (1) | AU2008216356C1 (ja) |
BR (1) | BRPI0807282A2 (ja) |
CA (1) | CA2677690C (ja) |
DK (1) | DK2120570T3 (ja) |
ES (1) | ES2384481T3 (ja) |
HK (1) | HK1132882A1 (ja) |
MX (1) | MX2009008491A (ja) |
NZ (1) | NZ579169A (ja) |
PL (1) | PL2120570T3 (ja) |
SG (1) | SG174079A1 (ja) |
WO (1) | WO2008100926A1 (ja) |
ZA (1) | ZA200906186B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010518168A (ja) * | 2007-02-12 | 2010-05-27 | ディーエムアイ バイオサイエンシズ インコーポレイテッド | トラマドールの副作用の低減方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG174079A1 (en) * | 2007-02-12 | 2011-09-29 | Dmi Biosciences Inc | Treatment of comorbid premature ejaculation and erectile dysfunction |
CN103263435B (zh) * | 2013-05-17 | 2014-08-13 | 宋博 | 聚维酮碘的制药用途 |
MX369874B (es) * | 2013-11-29 | 2019-11-22 | Laboratorios Liomont S A De C V | Composicion farmaceutica para el tratamiento de la disfunción erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en gel. |
WO2015134695A1 (en) * | 2014-03-07 | 2015-09-11 | Vyrix Pharmaceuticals, Inc. | Method of mitigating the side effects of a phosphodiesterase type v inhibitor in a subject |
US20180071269A1 (en) | 2015-08-12 | 2018-03-15 | Tianxin Wang | Therapeutical methods, formulations and nutraceutical formulations |
KR101778688B1 (ko) | 2016-05-31 | 2017-09-15 | 한양대학교 에리카산학협력단 | 포스포다이에스터라제―5 억제제를 포함하는 약제학적 복합제제 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003516363A (ja) * | 1999-12-10 | 2003-05-13 | ヴィーヴィス, インコーポレイテッド | 勃起機能不全の処置のためのホスホジエステラーゼインヒビターの経粘膜投与 |
JP2003525845A (ja) * | 1997-10-28 | 2003-09-02 | ヴィヴァス・インコーポレイテッド | 勃起機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与 |
JP2004532828A (ja) * | 2001-03-16 | 2004-10-28 | ディーエムアイ バイオサイエンシズ インコーポレイテッド | 射精遅延の方法 |
JP2005519851A (ja) * | 2001-06-21 | 2005-07-07 | ヴィヴァス・インコーポレイテッド | 早漏の治療のためのホスホジエステラーゼインヒビターの投与 |
JP2009519350A (ja) * | 2005-12-13 | 2009-05-14 | トリニティ ラボラトリーズ インコーポレイテッド | ヒトにおける早漏を治療するための方法 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US533669A (en) | 1895-02-05 | And conveying appaeatus | ||
US3830934A (en) | 1967-07-27 | 1974-08-20 | Gruenenthal Chemie | Analgesic and antitussive compositions and methods |
US3652589A (en) * | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
US4127118B1 (en) | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
NZ270871A (en) | 1990-04-25 | 1999-05-28 | Vivus Inc | Method for treating erectile dysfunction |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
US5151448A (en) | 1991-07-12 | 1992-09-29 | Crenshaw Roger T | Method for treating premature ejaculation |
AU651247B2 (en) * | 1991-09-06 | 1994-07-14 | Mcneilab, Inc. | Composition comprising a tramadol material and acetaminophen and its use |
US5223541A (en) * | 1991-09-13 | 1993-06-29 | Mcneilab, Inc. | Tramadol n-oxide material, enantiomers and compositions thereof, and their use |
US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US20010006967A1 (en) * | 1992-09-21 | 2001-07-05 | Stanley M. Crain | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
USRE36547E (en) * | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
US5472943A (en) * | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
US6096756A (en) * | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
NZ260408A (en) | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
GB9301192D0 (en) * | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
DE4329794C2 (de) * | 1993-09-03 | 1997-09-18 | Gruenenthal Gmbh | Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung |
GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
US5861431A (en) | 1995-06-07 | 1999-01-19 | Iotek, Inc. | Incontinence treatment |
GB9514464D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
US6017963A (en) * | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
DE19601744C2 (de) | 1996-01-19 | 1998-04-16 | Gruenenthal Gmbh | Verfahren zur Herstellung der Enantiomeren von O-Demethyltramadol |
DE19601745C1 (de) * | 1996-01-19 | 1997-10-09 | Gruenenthal Gmbh | Verfahren zur Racematspaltung von Tramadol |
IL119121A (en) * | 1996-08-22 | 2000-11-21 | Chemagis Ltd | Process for the purification of (RR-SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol hydrochloride |
US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
CN1251987A (zh) * | 1997-03-11 | 2000-05-03 | 达尔文发现有限公司 | 含有r-和s-对映体分离部分的剂型 |
EP1005861B1 (en) * | 1997-04-11 | 2005-06-29 | Nippon Shinyaku Co., Ltd. | Remedies for frequent urination and urinary incontinence |
US6037360A (en) | 1997-10-28 | 2000-03-14 | Vivus, Incorporated | Administration of 5-HT3 receptor antagonists to treat premature ejaculation |
BR9812785A (pt) * | 1997-11-12 | 2000-10-10 | Bayer Ag | "imidazotriazinonas 2-fenil-substituìdas como inibidores de fosfodiesterase" |
US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
SI2266564T1 (sl) * | 1997-12-22 | 2013-07-31 | Euro-Celtique S.A. | Farmacevtska oralna dozirna oblika, ki vsebuje kombinacijo opioidnega agonista in opioidnega antagonista |
BR9813826A (pt) * | 1997-12-22 | 2000-10-10 | Euro Celtique Sa | Potencial de uso abusivo de administração oral de opióide analgésico |
US6339826B2 (en) * | 1998-05-05 | 2002-01-15 | International Business Machines Corp. | Client-server system for maintaining a user desktop consistent with server application user access permissions |
US6156342A (en) * | 1998-05-26 | 2000-12-05 | Andex Pharmaceuticals, Inc. | Controlled release oral dosage form |
US6403605B1 (en) * | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
US6339106B1 (en) * | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
US6476078B2 (en) * | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
US6943166B1 (en) * | 1999-04-30 | 2005-09-13 | Lilly Icos Llc. | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
US6765010B2 (en) * | 1999-05-06 | 2004-07-20 | Pain Therapeutics, Inc. | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
US20030055070A1 (en) * | 1999-07-01 | 2003-03-20 | Wilma Harrison | Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction |
US6821975B1 (en) * | 1999-08-03 | 2004-11-23 | Lilly Icos Llc | Beta-carboline drug products |
US6451806B2 (en) * | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
AU1164601A (en) * | 1999-11-09 | 2001-06-06 | Darwin Discovery Limited | Therapeutic use and formulation |
US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
US20020091129A1 (en) * | 2000-11-20 | 2002-07-11 | Mitradev Boolell | Treatment of premature ejaculation |
CA2778114A1 (en) * | 2001-05-11 | 2002-11-21 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
DK1414451T3 (da) * | 2001-08-06 | 2009-08-10 | Euro Celtique Sa | Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist |
US7019010B2 (en) * | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
MXPA04004370A (es) * | 2001-11-09 | 2004-08-11 | Schering Corp | Derivados policiclicos de guanina inhibidores de fosfodiesterasa v. |
WO2004069167A2 (en) * | 2003-01-31 | 2004-08-19 | Nastech Pharmaceutical Company Inc. | Method and compositions for treating male infertility |
US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
US20050054688A1 (en) * | 2003-08-08 | 2005-03-10 | Pfizer Inc | Selective serotonin reuptake inhibitors in the treatment of disease |
US20060149480A1 (en) * | 2004-02-26 | 2006-07-06 | Lundeen James E | Method of making combination medicament and medicament made thereby |
US7483535B2 (en) * | 2004-09-15 | 2009-01-27 | Hewlett-Packard Development Company, L.P. | Transmission of generalized scalable bit-streams |
US20070185145A1 (en) * | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
SG174079A1 (en) * | 2007-02-12 | 2011-09-29 | Dmi Biosciences Inc | Treatment of comorbid premature ejaculation and erectile dysfunction |
AU2008216363B2 (en) * | 2007-02-12 | 2014-05-08 | Aytu Bioscience, Inc. | Reducing side effects of tramadol |
US20100120780A1 (en) * | 2007-04-19 | 2010-05-13 | Chandra Ulagaraj Singh | Treatments for premature ejaculation in humans |
-
2008
- 2008-02-12 SG SG2011058682A patent/SG174079A1/en unknown
- 2008-02-12 KR KR1020157017473A patent/KR20150089085A/ko not_active Application Discontinuation
- 2008-02-12 NZ NZ579169A patent/NZ579169A/en not_active IP Right Cessation
- 2008-02-12 DK DK08729644.8T patent/DK2120570T3/da active
- 2008-02-12 ES ES08729644T patent/ES2384481T3/es active Active
- 2008-02-12 WO PCT/US2008/053710 patent/WO2008100926A1/en active Application Filing
- 2008-02-12 EP EP12167624A patent/EP2486927A1/en not_active Withdrawn
- 2008-02-12 BR BRPI0807282-5A2A patent/BRPI0807282A2/pt not_active IP Right Cessation
- 2008-02-12 AU AU2008216356A patent/AU2008216356C1/en not_active Ceased
- 2008-02-12 KR KR1020147007397A patent/KR20140054312A/ko not_active Application Discontinuation
- 2008-02-12 MX MX2009008491A patent/MX2009008491A/es active IP Right Grant
- 2008-02-12 US US12/029,783 patent/US20080262094A1/en not_active Abandoned
- 2008-02-12 EP EP08729644A patent/EP2120570B1/en active Active
- 2008-02-12 KR KR1020097018878A patent/KR20090121315A/ko not_active Application Discontinuation
- 2008-02-12 CA CA2677690A patent/CA2677690C/en not_active Expired - Fee Related
- 2008-02-12 PL PL08729644T patent/PL2120570T3/pl unknown
- 2008-02-12 JP JP2009549684A patent/JP2010518167A/ja active Pending
- 2008-02-12 CN CN2008800118025A patent/CN101657101B/zh not_active Expired - Fee Related
-
2009
- 2009-09-07 ZA ZA2009/06186A patent/ZA200906186B/en unknown
- 2009-12-15 HK HK09111745.6A patent/HK1132882A1/xx not_active IP Right Cessation
-
2011
- 2011-09-28 US US13/247,387 patent/US20120018345A1/en not_active Abandoned
- 2011-09-28 US US13/247,347 patent/US20120022071A1/en not_active Abandoned
-
2013
- 2013-12-20 JP JP2013264162A patent/JP2014077008A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003525845A (ja) * | 1997-10-28 | 2003-09-02 | ヴィヴァス・インコーポレイテッド | 勃起機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与 |
JP2003516363A (ja) * | 1999-12-10 | 2003-05-13 | ヴィーヴィス, インコーポレイテッド | 勃起機能不全の処置のためのホスホジエステラーゼインヒビターの経粘膜投与 |
JP2004532828A (ja) * | 2001-03-16 | 2004-10-28 | ディーエムアイ バイオサイエンシズ インコーポレイテッド | 射精遅延の方法 |
JP2005519851A (ja) * | 2001-06-21 | 2005-07-07 | ヴィヴァス・インコーポレイテッド | 早漏の治療のためのホスホジエステラーゼインヒビターの投与 |
JP2009519350A (ja) * | 2005-12-13 | 2009-05-14 | トリニティ ラボラトリーズ インコーポレイテッド | ヒトにおける早漏を治療するための方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010518168A (ja) * | 2007-02-12 | 2010-05-27 | ディーエムアイ バイオサイエンシズ インコーポレイテッド | トラマドールの副作用の低減方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2120570A4 (en) | 2010-03-31 |
KR20150089085A (ko) | 2015-08-04 |
HK1132882A1 (en) | 2010-03-12 |
WO2008100926A1 (en) | 2008-08-21 |
JP2014077008A (ja) | 2014-05-01 |
EP2120570B1 (en) | 2012-05-16 |
EP2486927A1 (en) | 2012-08-15 |
KR20090121315A (ko) | 2009-11-25 |
AU2008216356A1 (en) | 2008-08-21 |
PL2120570T3 (pl) | 2012-10-31 |
US20080262094A1 (en) | 2008-10-23 |
AU2008216356C1 (en) | 2014-07-24 |
SG174079A1 (en) | 2011-09-29 |
KR20140054312A (ko) | 2014-05-08 |
EP2120570A1 (en) | 2009-11-25 |
CN101657101A (zh) | 2010-02-24 |
NZ579169A (en) | 2012-05-25 |
CA2677690A1 (en) | 2008-08-21 |
ZA200906186B (en) | 2013-02-27 |
CA2677690C (en) | 2012-05-15 |
BRPI0807282A2 (pt) | 2014-04-29 |
DK2120570T3 (da) | 2012-06-25 |
MX2009008491A (es) | 2010-01-20 |
CN101657101B (zh) | 2013-12-11 |
US20120018345A1 (en) | 2012-01-26 |
ES2384481T3 (es) | 2012-07-05 |
US20120022071A1 (en) | 2012-01-26 |
AU2008216356B2 (en) | 2014-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5550101B2 (ja) | トラマドールの副作用の低減薬の製造におけるトラマドールおよびpde阻害剤の使用方法 | |
JP2014077008A (ja) | 併存する早漏及び勃起障害を治療するための治療剤、製薬組成物及びキット | |
JP4377585B2 (ja) | 射精遅延の方法 | |
AU2002252361A1 (en) | Method of delaying ejaculation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100621 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110210 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111124 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130115 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130412 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130419 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130614 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130621 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130712 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130820 |